The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease.
Open accessAbstract
A neuropathological hallmark of Alzheimer disease (AD) is a widespread amyloid deposition. We analyzed the entire amino acid sequences in an amyloid preparation and found, in addition to the major beta/A4-protein (A beta) fragment, two unknown peptides. We raised antibodies against synthetic peptides using subsequences of these peptides. These antibodies immunostained amyloid in neuritic and diffuse plaques as well as vascular amyloid. Electron microscopic analysis demonstrated that the immunostaining was localized on amyloid fibrils. We have isolated an apparently full-length cDNA encoding a 140-amino-acid protein within which two previously unreported amyloid sequences are encoded in tandem in the most hydrophobic domain. We tentatively named this 35-amino acid peptide NAC (non-A beta component of AD amyloid) and its precursor NACP. NAC is the second component, after A beta, identified chemically in the purified AD amyloid preparation. Secondary structure predictions indicate that the NAC peptide sequence has a strong tendency to form beta-structures consistent with its association with amyloid. NACP is detected as a M(r) 19,000 protein in the cytosolic fraction of brain homogenates and comigrates on immunoblots with NACP synthesized in Escherichia coli from NACP cDNA. NACP mRNA is expressed principally in brain but is also expressed in low concentrations in all tissues examined except in liver, suggesting its ubiquitous and brain-specific functions. The availability of the cDNA encoding full-length NACP should help to elucidate the mechanisms of amyloidosis in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A simple method for displaying the hydropathic character of a protein
Kyte, J., & Doolittle, R. F. (1982) · Journal of Molecular Biology · doi:10.1016/0022-2836(82)90515-0 · Cited by 22,843
Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease
Chirgwin, J. M., Przybyla, A. E., MacDonald, R. J., & Rutter, W. J. (1979) · Biochemistry · doi:10.1021/bi00591a005 · Cited by 21,725
Saiki, R. K., Scharf, S., Faloona, F., Mullis, K. B., Horn, G. T., Erlich, H. A., & Arnheim, N. (1985) · Science · doi:10.1126/science.2999980 · Cited by 8,956
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs
Kozak, M. (1987) · Nucleic Acids Research · doi:10.1093/nar/15.20.8125 · Cited by 5,087
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619
Garnier, J., Osguthorpe, D. J., & Robson, B. (1978) · Journal of Molecular Biology · doi:10.1016/0022-2836(78)90297-8 · Cited by 4,523
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Cited by
Items 101–170 of 170
Immune Signaling in Neurodegeneration
Hammond, T. R., Marsh, S. E., & Stevens, B. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.016 · Cited by 336
NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease
Wakabayashi, K., Matsumoto, K., Takayama, K., Yoshimoto, M., & Takahashi, H. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00891-4 · Cited by 331
Self-citationStructural Organization of α-Synuclein Fibrils Studied by Site-directed Spin Labeling
Der-Sarkissian, A., Jao, C. C., Chen, J., & Langen, R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305266200 · Cited by 329
Targeting Alpha-Synuclein as a Therapy for Parkinson’s Disease
Fields, C. R., Bengoa-Vergniory, N., & Wade-Martins, R. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00299 · Cited by 328
The role of amyloid β peptide 42 in Alzheimer's disease
Findeis, M. A. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.06.006 · Cited by 324
Games, D., Valera, E., Spencer, B., Rockenstein, E., Mante, M., Adame, A., Patrick, C., Ubhi, K., Nuber, S., Sacayon, P., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.5314-13.2014 · Cited by 322
Self-citationStaging/typing of Lewy body related α-synuclein pathology: a study of the BrainNet Europe Consortium
Alafuzoff, I., Ince, P. G., Arzberger, T., Al-Sarraj, S., Bell, J., Bodi, I., Bogdanovic, N., Bugiani, O., Ferrer, I., Gelpi, E., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0523-2 · Cited by 322
Ono, K., & Yamada, M. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03707.x · Cited by 320
Lavedan, C. (1998) · Genome Research · doi:10.1101/gr.8.9.871 · Cited by 320
α‐Synuclein and Parkinson's disease
Recchia, A., Debetto, P., Negro, A., Guidolin, D., Skaper, S. D., & Giusti, P. (2004) · The FASEB Journal · doi:10.1096/fj.03-0338rev · Cited by 318
Uversky, V. N. (2003) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-003-3096-6 · Cited by 314
The physiological role of α‐synuclein and its relationship to Parkinson’s Disease
Sulzer, D., & Edwards, R. H. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14810 · Cited by 312
The facial nerve axotomy model
Moran, L. B., & Graeber, M. B. (2004) · Brain Research Reviews · doi:10.1016/j.brainresrev.2003.11.004 · Cited by 306
Genetics of Parkinson's disease and parkinsonism
Hardy, J., Cai, H., Cookson, M. R., Gwinn‐Hardy, K., & Singleton, A. (2006) · Annals of Neurology · doi:10.1002/ana.21022 · Cited by 303
α‐Synuclein oligomers and clinical implications for Parkinson disease
Kalia, L. V., Kalia, S. K., McLean, P. J., Lozano, A. M., & Lang, A. E. (2013) · Annals of Neurology · doi:10.1002/ana.23746 · Cited by 292
Mutation E46K increases phospholipid binding and assembly into filaments of human α‐synuclein
Choi, W., Zibaee, S., Jakes, R., Serpell, L. C., Davletov, B., Anthony Crowther, R., & Goedert, M. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.09.038 · Cited by 286
Alpha-synuclein structure, functions, and interactions
Emamzadeh, F. N. (2016) · Journal of Research in Medical Sciences · doi:10.4103/1735-1995.181989 · Cited by 286
Alpha-synuclein: from secretion to dysfunction and death
Marques, O., & Outeiro, T. F. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.94 · Cited by 286
Han, H., Weinreb, P. H., & Lansbury, P. T. (1995) · Chemistry & Biology · doi:10.1016/1074-5521(95)90071-3 · Cited by 284
Alpha-synuclein and Parkinson's disease
Lücking, C. B., & Brice*, A. (2000) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000671 · Cited by 279
Wiltfang, J., Esselmann, H., Bibl, M., Smirnov, A., Otto, M., Paul, S., Schmidt, B., Klafki, H. ‐., Maler, M., Dyrks, T., et al. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00818.x · Cited by 271
Lotharius, J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.20.2395 · Cited by 269
-Synuclein Phosphorylation Enhances Eosinophilic Cytoplasmic Inclusion Formation in SH-SY5Y Cells
Smith, W. W. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.0482-05.2005 · Cited by 268
Hashimoto, M., Hsu, L. J., Sisk, A., Xia, Y., Takeda, A., Sundsmo, M., & Masliah, E. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00514-9 · Cited by 267
Self-citationNeuropathology of synuclein aggregates: New insights into mechanisms of neurodegenerative diseases
Duda, J. E., Lee, V. M.-Y., & Trojanowski, J. Q. (2000) · Journal of Neuroscience Research · doi:10.1002/1097-4547(20000715)61:2<121::aid-jnr1>3.0.co;2-4 · Cited by 264
Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease
Dev, K. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00140-0 · Cited by 263
Interface between tauopathies and synucleinopathies: A tale of two proteins
Galpern, W. R., & Lang, A. E. (2006) · Annals of Neurology · doi:10.1002/ana.20819 · Cited by 263
Wang, Z., Udeshi, N. D., O'Malley, M., Shabanowitz, J., Hunt, D. F., & Hart, G. W. (2010) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m900268-mcp200 · Cited by 261
Tabner, B. J., Turnbull, S., El-Agnaf, O. M. A., & Allsop, D. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00801-8 · Cited by 260
El-Agnaf, O. M. A., Jakes, R., Curran, M. D., & Wallace, A. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01419-7 · Cited by 258
Cappai, R., Leck, S., Tew, D. J., Williamson, N. A., Smith, D. P., Galatis, D., Sharpies, R. A., Curtain, C. C., Ali, F. E., Cherny, R. A., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-3437fje · Cited by 257
Neurodegeneration and neuroprotection in Parkinson disease
Fahn, S., & Sulzer, D. (2004) · NeuroRX · doi:10.1602/neurorx.1.1.139 · Cited by 257
Quantification of α-Synuclein Binding to Lipid Vesicles Using Fluorescence Correlation Spectroscopy
Rhoades, E., Ramlall, T. F., Webb, W. W., & Eliezer, D. (2006) · Biophysical Journal · doi:10.1529/biophysj.105.079251 · Cited by 257
Residual Structure and Dynamics in Parkinson's Disease-associated Mutants of α-Synuclein
Bussell, R., & Eliezer, D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106777200 · Cited by 255
Shults, C. W., Rockenstein, E., Crews, L., Adame, A., Mante, M., Larrea, G., Hashimoto, M., Song, D., Iwatsubo, T., Tsuboi, K., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3527-05.2005 · Cited by 254
Self-citationAlpha‐synuclein in Lewy Body Disease and Alzheimer's Disease
Hashimoto, M., & Masliah, E. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00552.x · Cited by 254
Self-citationAre synucleinopathies prion-like disorders?
Angot, E., Steiner, J. A., Hansen, C., Li, J.-Y., & Brundin, P. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70213-1 · Cited by 251
Role of α-Synuclein in Inducing Innate and Adaptive Immunity in Parkinson Disease
Allen Reish, H. E., & Standaert, D. G. (2015) · Journal of Parkinson’s Disease · doi:10.3233/jpd-140491 · Cited by 244
Arima, K., Uéda, K., Sunohara, N., Arakawa, K., Hirai, S., Nakamura, M., Tonozuka-Uehara, H., & Kawai, M. (1998) · Acta Neuropathologica · doi:10.1007/s004010050917 · Cited by 239
“So far as we are aware, the synuclein family members have only been reported to be associated with neuronal membranes in the brain [4, 7]. However, our previous Northern blot analyses revealed that expression of the NACP gene was not restricted to the brain, but was also found in significant amounts in several non-neu…”
BackgroundResultInfluentialSelf-citationα‐Synuclein produces a long‐lasting increase in neurotransmitter release
Liu, S., Ninan, I., Antonova, I., Battaglia, F., Trinchese, F., Narasanna, A., Kolodilov, N., Dauer, W., Hawkins, R. D., & Arancio, O. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600451 · Cited by 198
Fluid Biomarkers for Synaptic Dysfunction and Loss
Camporesi, E., Nilsson, J., Brinkmalm, A., Becker, B., Ashton, N. J., Blennow, K., & Zetterberg, H. (2020) · Biomarker Insights · doi:10.1177/1177271920950319 · Cited by 165
Lewy Body Pathology in Alzheimer's Disease
Kotzbauer, P. T., Tojanowski, J. Q., & Lee, V. M. V. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:225 · Cited by 177
“The possibility of synuclein involvement in AD pathology was raised previously when two fragments of the protein were found to co-purify with amyloid plaque cores (Ueda et al., 1993).”
Arai, Y., Yamazaki, M., Mori, O., Muramatsu, H., Asano, G., & Katayama, Y. (2001) · Brain Research · doi:10.1016/s0006-8993(00)03082-1 · Cited by 173
Microglial Activation Parallels System Degeneration in Multiple System Atrophy
Ishizawa, K., Komori, T., Sasaki, S., Arai, N., Mizutani, T., & Hirose, T. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.1.43 · Cited by 172
Rodríguez-Rodríguez, C., Telpoukhovskaia, M., & Orvig, C. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.03.008 · Cited by 151
Mutant α-Synuclein Overexpression Mediates Early Proinflammatory Activity
Su, X., Federoff, H. J., & Maguire-Zeiss, K. A. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9053-x · Cited by 145
“…pathogenesis of PD. a-Synuclein, a 16–22 kDa protein with widespread nervous system distribution, was first isolated from the Torpedo cholinergic synaptic vesicles and later identified as the non-amyloid component of amyloid in Alzheimer’s disease patients (Maroteaux et al. 1988; Ueda et al. 1993).”
BackgroundBiology of Aβ Amyloid in Alzheimer's Disease
Wisniewski, T., Ghiso, J., & Frangione, B. (1997) · Neurobiology of Disease · doi:10.1006/nbdi.1997.0147 · Cited by 134
Could a loss of α‐synuclein function put dopaminergic neurons at risk?
Perez, R. G., & Hastings, T. G. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02423.x · Cited by 133
Immunotherapy for neurodegenerative diseases: Focus on α-synucleinopathies
Valera, E., & Masliah, E. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.013 · Cited by 132
Self-citationAmino acid sequence motifs and mechanistic features of the membrane translocation of α‐synuclein
Ahn, K. J., Paik, S. R., Chung, K. C., & Kim, J. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03731.x · Cited by 123
“It is also expressed in hematopoietic cells (Hashimoto et al. 1997; Shin et al. 2000) and in other tissues, such as the heart, skeletal muscle, pancreas, and placenta, but it is less abundant than in the brain (Ueda et al. 1993; Jakes et al. 1994).”
BackgroundInfluentialParkinsons Disease and other α-Synucleinopathies
Goedert, M. (2001) · Clinical Chemistry and Laboratory Medicine · doi:10.1515/cclm.2001.047 · Cited by 96
α-Synuclein in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment
Korff, A., Liu, C., Ginghina, C., Shi, M., Zhang, J., & Initiative, F. T. A. D. N. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-130458 · Cited by 95
Olivares, D., Huang, X., Branden, L., Greig, N. H., & Rogers, J. T. (2009) · International Journal of Molecular Sciences · doi:10.3390/ijms10031226 · Cited by 93
Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease
Nilsson, J., Gobom, J., Sjödin, S., Brinkmalm, G., Ashton, N. J., Svensson, J., Johansson, P., Portelius, E., Zetterberg, H., Blennow, K., et al. (2021) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12179 · Cited by 82
O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies
Permanne, B., Sand, A., Ousson, S., Nény, M., Hantson, J., Schubert, R., Wiessner, C., Quattropani, A., & Beher, D. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00057 · Cited by 82
Hashimoto, M., & Masliah, E. (2003) · Neurochemical Research · doi:10.1023/a:1026073324672 · Cited by 78
“-Synuclein is a 140-amino-acid (aa) presynaptic protein, that was previously identified as the precursor of the non– amyloid component of AD amyloid plaque (124) (Fig.”
BackgroundSelf-citationKawahata, I., & Fukunaga, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113779 · Cited by 71
Cheng, F., Li, X., Li, Y., Wang, C., Wang, T., Liu, G., Baskys, A., Uéda, K., Chan, P., & Yu, S. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07460.x · Cited by 73
Self-citationThe relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer’s disease
for the Dominantly Inherited Alzheimer Network (DIAN), Twohig, D., Rodriguez-Vieitez, E., Sando, S. B., Berge, G., Lauridsen, C., Møller, I., Grøntvedt, G. R., Bråthen, G., Patra, K., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0624-z · Cited by 68
Alzheimer’s disease and the autophagic-lysosomal system
Chung, K. M., Hernández, N., Sproul, A. A., & Yu, W. H. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2018.05.017 · Cited by 63
Majbour, N. K., Chiasserini, D., Vaikath, N. N., Eusebi, P., Tokuda, T., van de Berg, W., Parnetti, L., Calabresi, P., & El-Agnaf, O. M. A. (2017) · Scientific Reports · doi:10.1038/srep40263 · Cited by 55
Webber, E. K., Fivaz, M., Stutzmann, G. E., & Griffioen, G. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13065 · Cited by 50
Extracellular Alpha-Synuclein: Mechanisms for Glial Cell Internalization and Activation
Chavarría, C., Ivagnes, R., & Souza, J. M. (2022) · Biomolecules · doi:10.3390/biom12050655 · Cited by 47
Novel subcellular localization for α-synuclein: possible functional consequences
Guardia-Laguarta, C., Area-Gomez, E., Schon, E. A., & Przedborski, S. (2015) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2015.00017 · Cited by 44
Wang, Z.-Y., Han, Z.-M., Liu, Q.-F., Tang, W., Ye, K., & Yao, Y.-Y. (2015) · International Psychogeriatrics · doi:10.1017/s1041610215000447 · Cited by 39
Does Intrinsic Disorder in Proteins Favor Their Interaction with Lipids?
Deryusheva, E., Nemashkalova, E., Galloux, M., Richard, C., Eléouët, J., Kovacs, D., Van Belle, K., Tompa, P., Uversky, V., & Permyakov, S. (2019) · PROTEOMICS · doi:10.1002/pmic.201800098 · Cited by 34
Huntington, T. E., & Srinivasan, R. (2021) · Aging and disease · doi:10.14336/ad.2021.0517 · Cited by 34
The Cytotoxicity and Clearance of Mutant Huntingtin and Other Misfolded Proteins
Folger, A., & Wang, Y. (2021) · Cells · doi:10.3390/cells10112835 · Cited by 32
“Lewy bodies formed from α-synuclein are the causal agent behind Parkinson’s, and its aggregation is associated with a hydrophobic central domain known as non-amyloid βcomponent domain [9].”
BackgroundKawahata, I., Tokuoka, H., Parvez, H., & Ichinose, H. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0304-z · Cited by 31
Doublecortin-like Kinase 1 Regulates α-Synuclein Levels and Toxicity
Vázquez-Vélez, G. E., Gonzales, K. A., Revelli, J.-P., Adamski, C. J., Alavi Naini, F., Bajić, A., Craigen, E., Richman, R., Heman-Ackah, S. M., Wood, M. J. A., et al. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.1076-19.2019 · Cited by 22
“The role of -Syn in PD and other synucleinopathies has been under intense study since its discovery 30 years ago (Maroteaux et al., 1988; Uéda et al., 1993; Spillantini et al., 1998).”
Background
Metadata
- Authors
- Uéda, K., Fukushima, H., Masliah, E., Xia, Y., Iwai, A., Yoshimoto, M., Otero, D. A., Kondo, J., Ihara, Y., & Saitoh, T.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1993-12
- Volume
- 90
- Issue
- 23
- Pages
- 11282-11286
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2013313629
- Cited by
- 1,480
- References
- 47
- FWCI
- 4.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.